

# DEXTRANS

## Current Concepts of Basic Actions and Clinical Applications

*Compiled and Edited by*

**JOHN R. DERRICK, M.D.**

*Professor and Chief  
Division of Thoracic  
and Cardiovascular Surgery  
University of Texas Medical Branch  
Galveston, Texas*

**M. MASON GUEST, Ph.D.**

*Professor and Chairman  
Department of Physiology  
University of Texas Medical Branch  
Galveston, Texas*

### CONTRIBUTORS


Benjamin Alexander  
Marion I. Barnhart  
Walter L. Bloom  
Ted P. Bond  
Richard W. Brown  
John R. Derrick  
Lars-Erik Gelin  
John Gilroy

Magnus I. Gregersen  
M. Mason Guest  
Robert M. Hardaway  
Lerner B. Hinshaw  
Harry Hint  
Paul M. James, Jr.  
Robert D. Langdell  
~~Per H. Langsjöen~~

William H. Lee  
Richard Lillehei  
William G. Manax  
J. Sterling Meyer  
John A. Moncrief  
Eric Ponder  
Raymond C. Read  
Thomas K. Shires

**CHARLES C THOMAS • PUBLISHER**

*Springfield • Illinois • U.S.A.*



# DEXTRANS

Current Concepts of Basic Actions  
and Clinical Applications

*Compiled and Edited by*


**JOHN R. DERRICK, M.D.**

*Professor and Chief  
Division of Thoracic and Cardiovascular Surgery  
University of Texas Medical Branch  
Galveston, Texas*

*and*

**M. MASON GUEST, Ph.D.**

*Professor and Chairman  
Department of Physiology  
University of Texas Medical Branch  
Galveston, Texas*



**CHARLES C THOMAS • PUBLISHER**

*Springfield • Illinois • U.S.A.*

*Published and Distributed Throughout the World by*  
CHARLES C THOMAS • PUBLISHER  
BANNERSTONE HOUSE  
301-327 East Lawrence Avenue, Springfield, Illinois, U.S.A.  
NATCHEZ PLANTATION HOUSE  
735 North Atlantic Boulevard, Fort Lauderdale, Florida, U.S.A.

This book is protected by copyright. No  
part of it may be reproduced in any manner  
without written permission from the publisher.

© 1971, by CHARLES C THOMAS • PUBLISHER  
Library of Congress Catalog Card Number: 70-143735

*With THOMAS BOOKS careful attention is given to all details of  
manufacturing and design. It is the Publisher's desire to present books  
that are satisfactory as to their physical qualities and artistic possibilities  
and appropriate for their particular use. THOMAS BOOKS will be true  
to those laws of quality that assure a good name and good will.*

*Printed in the United States of America*

*B-7*

## **DEXTRANS**

**Current Concepts of  
Basic Actions and Clinical Applications**

**The First International Symposium on Dextrans**  
**Galveston, Texas**

## CONTRIBUTORS

**BENJAMIN ALEXANDER, M.D.**

*Senior Investigator  
New York Blood Center  
New York, New York*

**MARION I. BARNHART, Ph.D.**

*Wayne State University School of Medicine  
Detroit, Michigan*

**WALTER L. BLOOM, M.D.**

*Assistant to the Vice President for Academic Affairs and  
Professor of Applied Biology  
Georgia Institute of Technology  
Atlanta, Georgia*

**TED P. BOND, M.A.**

*Research Assistant Professor  
Department of Physiology  
University of Texas Medical Branch  
Galveston, Texas*

**RICHARD W. BROWN**

*Clinical Associate  
Division of Thoracic and Cardiovascular Surgery  
University of Texas Medical Branch  
Galveston, Texas*

**JOHN R. DERRICK, M.D.**

*Professor and Chief  
Division of Thoracic and Cardiovascular Surgery  
University of Texas Medical Branch  
Galveston, Texas*

**LARS-ERIK GELIN, M.D.**

*Professor, Department of Surgery  
University of Gothenburg  
Gothenburg, Sweden*

**JOHN GILROY**

*Professor and Chairman  
Department of Neurology  
Wayne State University School of Medicine  
Detroit, Michigan*

**MAGNUS I. GREGERSEN, Ph.D.\***

*Dalton Professor of Physiology  
Laboratory of Hemorheology  
College of Physicians and Surgeons  
Columbia University  
New York, New York*

**M. MASON GUEST, Ph.D.**

*Professor and Chairman  
Department of Physiology  
University of Texas Medical Branch  
Galveston, Texas*

**ROBERT M. HARDAWAY**

*Col. MC USA  
97th General Hospital  
Frankfurt, Germany*

**LERNER B. HINSHAW, Ph.D.**

*Professor, Department of Physiology  
University of Oklahoma School of Medicine  
Oklahoma City, Oklahoma*

**HARRY HINT, M.D.**

*Assistant Director of Research  
Pharmacia, A. B.  
Uppsala, Sweden*

---

\* deceased

**PAUL M. JAMES, JR., M.D.**

*Director, Residency and Internship Program  
Hahnemann Medical College and Hospital  
Philadelphia, Pennsylvania*

**ROBERT D. LANGDELL, M.D.**

*Professor of Pathology  
University of North Carolina School of Medicine  
Chapel Hill, North Carolina*

**PER H. LANGSJOEN, M.D.**

*Chief of Cardiology  
Scott and White Clinic  
Temple, Texas*

**WILLIAM H. LEE, M.D.**

*Chairman, Division of Thoracic Surgery  
Medical College of South Carolina  
Charleston, South Carolina*

**RICHARD LILLEHEI, M.D.**

*Professor of Surgery  
University of Minnesota Medical School  
Minneapolis, Minnesota*

**WILLIAM G. MANAX, M.D.**

*Assistant Professor of Surgery  
University of Minnesota Medical School  
Minneapolis, Minnesota*

**J. STERLING MEYER**

*Professor and Chairman  
Department of Neurology  
Baylor College of Medicine  
Houston, Texas*

**JOHN A. MONCRIEF, M.D.**

*Director, United States Army Surgical Research Unit  
Brook Army Medical Center  
Fort Sam Houston, Texas*



**ERIC PONDER, M.D.**

*Investigator  
Institute de Pathologie Cellulaire  
Kremlin-Bicêtre  
Paris, France*

**RAYMOND C. READ, M.D.**

*Chief of Surgical Service  
Veterans Administration Hospital  
Little Rock, Arkansas*

**THOMAS K. SHIRES**

*Veterans Administration Hospital  
Department of Urology  
University of Oklahoma Medical Center  
Oklahoma City, Oklahoma*

## PREFACE

**D**URING the past two decades, numerous research and clinical reports about the benefits—and hazards—of dextrans in cardiovascular and related disease have appeared in the literature. Many questions still remain unanswered about these agents, but the consensus is that they do have therapeutic value for some conditions.

Because of the widespread interest and unanswered questions, it seemed obvious that a symposium, at which experiences, ideas, and opinions could be exchanged by authorities knowledgeable about dextrans, would be valuable. Such a symposium would also provide a way to disseminate currently available knowledge, both research and clinical, to a large segment of the medical population. Therefore, several interested organizations elected to sponsor the First International Symposium on Dextrans which was held in Galveston, Texas, on May 19 and 20, 1968.

This volume is made up of discussions given at that symposium. Those interested in the subject of dextrans will find this book most informative, both as to what is now known and as to what questions are under investigation.

JOHN R. DERRICK, M.D.  
M. MASON GUEST, PH.D.

## ACKNOWLEDGMENTS

SINCERE appreciation is expressed to Abbott Laboratories for their generous educational grant in support of the First International Symposium on Dextran.

Co-sponsors of the symposium were the Texas Heart Association, the Council on Circulation of the American Heart Association, The University of Texas Medical Branch Postgraduate Education Division, the University of Minnesota Medical School, and the Biomedical Division of the Georgia Institute of Technology.

The Editors and the Sponsors wish to thank all of those persons who helped to make the symposium a success.

The opening remarks were made by Doctor Truman Blocker who had over a decade previously helped to stimulate interest in the first conference concerning the Dextran.

Special notice should be taken of Pharmacia Laboratories who assisted with the cost of editing and compiling the manuscript.

# CONTENTS

	<i>Page</i>
<i>Contributors</i> .....	v
<i>Preface</i> .....	ix
<i>Acknowledgements</i> .....	xi
<i>Chapter</i>	
I. RELATIONSHIPS BETWEEN THE CHEMICAL AND PHYSICO-CHEMICAL PROPERTIES OF DEXTRAN AND ITS PHARMACOLOGICAL EFFECTS	
<i>Harry Hint</i> .....	3
II. EFFECTS OF ARTIFICIAL EXPANDER AGENTS ON BLOOD VISCOSITY	
<i>Magnus I. Gregersen</i> .....	27
III. HYPERVOLEMIA AND HEMODILUTION IN CERTAIN EFFECTS OF LOW MOLECULAR WEIGHT DEXTRAN	
<i>Raymond C. Read</i> .....	39
IV. INTERACTION OF DEXTRANS WITH SERUM PROTEINS, AND THEIR INTERACTION WITH RED CELLS AND PLATELETS	
<i>Eric Ponder</i> .....	54
V. EFFECT OF DEXTRAN ON RENAL HEMODYNAMICS	
<i>Lerner B. Hinshaw and Thomas K. Shires</i> .....	62
VI. DEXTRANS IN ORGAN TRANSPLANTATION	
<i>William G. Manax</i> .....	73
VII. SPECIFICITY OF SHARPLY CUT DEXTRAN FRACTION TO INHIBIT THROMBUS PROPAGATION	
<i>John A. Moncrief</i> .....	77
DISCUSSION— <i>William H. Lee</i> .....	82

VIII. COATING ACTION OF DEXTRANS	
<i>Walter L. Bloom</i> .....	86
IX. EFFECTS OF DEXTRAN AND OTHER MACROMOLECULES ON COAGULATION AND HEMOSTASIS	
<i>Benjamin Alexander</i> .....	93
X. ADSORPTION OF RADIOACTIVE DEXTRAN ON RED CELLS	
<i>Robert D. Langdell</i> .....	130
XI. RHEOLOGICAL EFFECTS OF DEXTRAN	
<i>Lars-Erik Gelin</i> .....	137
XII. EFFECTS OF DEXTRAN ON MICROCIRCULATORY FLOW	
<i>M. Mason Guest and Ted P. Bond</i> .....	154
XIII. PLATELET FUNCTION IN ACUTE STROKE PATIENTS TREATED WITH RHEOMACRODEX	
<i>Marion I. Barnhart, John Gilroy and J. Sterling     Meyer</i> .....	162
XIV. DEXTRANS IN SHOCK: EXPERIMENTAL AND CLINICAL OBSER- VATIONS	
<i>Richard Lillehei</i> .....	180
XV. DEXTRANS IN BATTLE CASUALTIES: BENEFITS AND HAZARDS	
<i>Paul M. James, Jr.</i> .....	186
XVI. DEXTRANS IN ISCHEMIC STATES	
<i>John R. Derrick and Richard W. Brown</i> .....	194
XVII. CLINICAL EXPERIENCE WITH LOW MOLECULAR WEIGHT DEXTRAN IN ISCHEMIC PROBLEMS	
<i>Per H. Langsjoen</i> .....	203
XVIII. SUMMARY	
<i>M. Mason Guest</i> .....	209
<i>Index</i> .....	211

## **DEXTRANS**

**Current Concepts of  
Basic Actions and Clinical Applications**



# I

## RELATIONSHIPS BETWEEN THE CHEMICAL AND PHYSICOCHEMICAL PROPERTIES OF DEXTRAN AND ITS PHARMACOLOGICAL EFFECTS

HARRY HINT

THE structural formula of dextran is shown in Figure I-1. This material was considered initially to be devoid of pharmacological effects apart from those concerned with its plasma volume expanding activity.

However, it is now known that dextran has several distinct pharmacological effects. These may be divided into two categories: effects which are determined by the physicochemical properties of




FIGURE I-1. A fraction of the structural formula of dextran molecule.



dextran solutions used and effects which are specific to dextran molecules.

Three different pharmacological effects of dextran are of definite clinical interest: plasma volume expansion, flow improvement, and antithrombotic effect. Dextran also lowers plasma lipid levels. This may also be of clinical interest.

### EFFECTS DETERMINED BY PHYSICOCHEMICAL PROPERTIES

*Plasma volume expansion and flow improvement* by dextran depend on the physicochemical properties of the solutions used. The principal factors that determine the physicochemical properties of dextran solutions are a) the molecular size, b) the molecular size distribution, and c) the final concentration of dextran in solution. Since properties such as colloid osmotic pressure, colloid osmotic effects, water-retaining capacity, viscosity, the effects of dextran on red cell aggregation and transport of dextran through capillary membranes may be varied profoundly by varying the physicochemical properties of dextran solutions, it is obvious that a study of the physicochemical properties of dextran solutions in relation to the molecular weight and concentration of dextran forms a basis for understanding the pharmacological effects of dextran.

The purpose of this paper is, therefore, to summarize some elementary facts, based mainly on the experimental data from our Research Department in Uppsala.

*The relationships between the colloid concentration and colloid osmotic pressure (c.o.p.)* for a dextran fraction comparable to clinical dextran (Macrodex®) and for normal plasma are presented in Figure I-2 and equations (1), (2), and (3).

$$\pi = \frac{RT}{M} C \quad (1)$$

$$\pi = \frac{RT}{M} C + AC^2 \quad (2)$$

$$\frac{\pi}{C} = \frac{RT}{M} + AC \quad (3)$$